[go: up one dir, main page]

PL2946765T3 - Ciekła kompozycja farmaceutyczna - Google Patents

Ciekła kompozycja farmaceutyczna

Info

Publication number
PL2946765T3
PL2946765T3 PL14169753T PL14169753T PL2946765T3 PL 2946765 T3 PL2946765 T3 PL 2946765T3 PL 14169753 T PL14169753 T PL 14169753T PL 14169753 T PL14169753 T PL 14169753T PL 2946765 T3 PL2946765 T3 PL 2946765T3
Authority
PL
Poland
Prior art keywords
pharmaceutical composition
liquid pharmaceutical
liquid
composition
pharmaceutical
Prior art date
Application number
PL14169753T
Other languages
English (en)
Inventor
Gianluca Rinaldi
Silvia Fratarcangeli
Rio Alessandra Del
Original Assignee
Ares Trading S.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50774704&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL2946765(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ares Trading S.A. filed Critical Ares Trading S.A.
Publication of PL2946765T3 publication Critical patent/PL2946765T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Dermatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Inorganic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Infusion, Injection, And Reservoir Apparatuses (AREA)
PL14169753T 2014-05-23 2014-05-23 Ciekła kompozycja farmaceutyczna PL2946765T3 (pl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP14169753.2A EP2946765B1 (en) 2014-05-23 2014-05-23 Liquid pharmaceutical composition

Publications (1)

Publication Number Publication Date
PL2946765T3 true PL2946765T3 (pl) 2017-08-31

Family

ID=50774704

Family Applications (2)

Application Number Title Priority Date Filing Date
PL14169753T PL2946765T3 (pl) 2014-05-23 2014-05-23 Ciekła kompozycja farmaceutyczna
PL15722541T PL3145487T3 (pl) 2014-05-23 2015-05-15 Ciekła kompozycja farmaceutyczna

Family Applications After (1)

Application Number Title Priority Date Filing Date
PL15722541T PL3145487T3 (pl) 2014-05-23 2015-05-15 Ciekła kompozycja farmaceutyczna

Country Status (25)

Country Link
US (7) US10426832B2 (pl)
EP (4) EP3050557A1 (pl)
JP (1) JP6334819B2 (pl)
KR (4) KR20230004960A (pl)
CN (2) CN106456538A (pl)
AU (3) AU2015263340B2 (pl)
BR (2) BR112016026879A8 (pl)
CA (2) CA2946953C (pl)
CY (1) CY1120681T1 (pl)
DK (2) DK2946765T3 (pl)
ES (3) ES2600488T3 (pl)
HR (2) HRP20181479T1 (pl)
HU (2) HUE029849T2 (pl)
IL (3) IL249115B (pl)
LT (2) LT2946765T (pl)
MX (1) MX361061B (pl)
NZ (1) NZ725360A (pl)
PL (2) PL2946765T3 (pl)
PT (2) PT2946765T (pl)
RS (2) RS55548B1 (pl)
RU (2) RU2719431C2 (pl)
SG (3) SG11201608745QA (pl)
SI (2) SI2946765T1 (pl)
SM (1) SMT201800454T1 (pl)
WO (1) WO2015177057A1 (pl)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2014337263B2 (en) 2013-10-16 2019-12-12 Outlook Therapeutics, Inc. Buffer formulations for enhanced antibody stability
WO2015151115A1 (en) 2014-04-02 2015-10-08 Intas Pharmaceuticals Limited Liquid pharmaceutical composition of adalimumab
ES2607489T3 (es) 2014-05-23 2017-03-31 Ares Trading S.A. Composición farmacéutica líquida
ES2600488T3 (es) 2014-05-23 2017-02-09 Ares Trading S.A. Composición farmacéutica líquida
ES2572919T3 (es) 2014-05-23 2016-06-03 Ares Trading S.A. Composición farmacéutica líquida
EP3247718B1 (en) 2015-01-21 2021-09-01 Outlook Therapeutics, Inc. Modulation of charge variants in a monoclonal antibody composition
WO2017136433A1 (en) * 2016-02-03 2017-08-10 Oncobiologics, Inc. Buffer formulations for enhanced antibody stability
HUE066142T2 (hu) * 2016-06-30 2024-07-28 Celltrion Inc Stabil folyékony gyógyszerészeti készítmény
EP3824906A1 (en) * 2016-12-21 2021-05-26 Amgen Inc. Anti-tnf alpha antibody formulations
CA3049857A1 (en) * 2017-01-11 2018-07-19 Celltrion Inc. Stable liquid formulation
IT201700004019A1 (it) * 2017-01-16 2018-07-16 Gk Pharma Consultans Sa Composizione comprendente carnitina, colato di sodio, acetato di sodio ed eventualmente argento per uso nel trattamento di psoriasi, vitiligine e rosacea
CN110621303A (zh) * 2017-03-16 2019-12-27 株式会社Lg化学 抗TNFα抗体的液体制剂
BR112019021723A2 (pt) * 2017-04-18 2021-06-29 Dr. Reddy's Laboratories Limited formulação de anticorpo líquida estável, anticorpo na formulação, formulação líquida estável de anticorpo anti-il6r, formulação líquida estável de tocilizumab em sistema de tampão de fosfato-aminoácido, e, formulação líquida estável de tocilizumab
JP2020534366A (ja) * 2017-09-20 2020-11-26 アルヴォテック エイチエフ アダリムマブ用医薬製剤
CN110151988A (zh) * 2018-02-11 2019-08-23 百奥泰生物制药股份有限公司 一种靶向治疗TNF-α相关疾病的人抗体制剂
WO2020138517A1 (ko) * 2018-12-24 2020-07-02 삼성바이오에피스 주식회사 항-TNFα 항체를 포함하는 약제학적 조성물
KR20210102954A (ko) * 2019-01-11 2021-08-20 삼성바이오에피스 주식회사 항체를 포함하는 약학적 조성물, 이를 포함하는 디바이스, 및 이의 용도
TW202128220A (zh) * 2019-10-08 2021-08-01 韓商三星Ｂｉｏｅｐｉｓ股份有限公司 穩定液體組合物、其製備方法及含有其之調配物
CN117642180A (zh) * 2021-05-05 2024-03-01 I2O治疗公司 用于治疗炎性疾病和自身免疫性疾病的离子液体制剂
JP2024544920A (ja) 2021-11-10 2024-12-05 アイ２オー セラピューティクス，インク． イオン液体組成物
CN120752054A (zh) 2023-03-16 2025-10-03 小野药品工业株式会社 抗体制剂
WO2025054112A2 (en) * 2023-09-08 2025-03-13 Merck Sharp & Dohme Llc Methods to control polysorbate degradation in biotherapeutic formulations

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6388197A (ja) 1986-09-30 1988-04-19 Tosoh Corp モノクロナル抗体の安定化方法
US6090382A (en) 1996-02-09 2000-07-18 Basf Aktiengesellschaft Human antibodies that bind human TNFα
NZ512006A (en) 1996-02-09 2005-05-27 Abbott Biotech Ltd Medical treatment with human TNF-alpha antibodies
US6171586B1 (en) 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
US5900404A (en) 1997-08-15 1999-05-04 Amgen Inc. Chemical modification of proteins to improve biocompatibility and bioactivity
US20040033228A1 (en) 2002-08-16 2004-02-19 Hans-Juergen Krause Formulation of human antibodies for treating TNF-alpha associated disorders
PT2335725T (pt) 2003-04-04 2017-01-06 Novartis Ag Formulações de elevada concentração de anticorpos e proteínas
WO2005072772A1 (en) 2004-01-30 2005-08-11 Suomen Punainen Risti Veripalvelu Pharmaceutical compositions
NZ552713A (en) 2004-07-23 2010-06-25 Genentech Inc Crystallization of anti-VEGF antibodies or fragments thereof using divalent cations
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
CA2600608A1 (en) 2005-03-08 2006-09-14 Pharmacia & Upjohn Company Llc Composition comprising human igg2 antibody and chelating agent
US8067547B2 (en) 2005-06-07 2011-11-29 ESBATech, an Alcon Biomedical Research Unit, LLC Stable and soluble antibodies inhibiting TNFα
CN104645329A (zh) 2007-11-30 2015-05-27 Abbvie公司 蛋白制剂及其制备方法
US8080518B2 (en) 2007-12-05 2011-12-20 Arbor Vita Corporation Co-administration of an agent linked to an internalization peptide with an anti-inflammatory
EP2362767B1 (en) 2008-10-29 2017-12-06 Ablynx N.V. Formulations of single domain antigen binding molecules
CA2742990A1 (en) 2008-11-17 2010-05-20 Genentech, Inc. Method and formulation for reducing aggregation of a macromolecule under physiological conditions
CA2760185A1 (en) * 2009-05-04 2010-11-11 Abbott Biotechnology Ltd. Stable high protein concentration formulations of human anti-tnf-alpha antibodies
RS61082B1 (sr) 2010-02-26 2020-12-31 Novo Nordisk As Stabilno antitelo koje sadrži kompozicije
CA2794929C (en) 2010-03-01 2018-06-05 Progenics Pharmaceuticals, Inc. Concentrated protein formulations and uses thereof
US20110223208A1 (en) 2010-03-09 2011-09-15 Beth Hill Non-Aqueous High Concentration Reduced Viscosity Suspension Formulations
WO2011119487A2 (en) 2010-03-22 2011-09-29 Genentech, Inc. Compositions and methods useful for stabilizing protein-containing formulations
EP2399604A1 (en) 2010-06-25 2011-12-28 F. Hoffmann-La Roche AG Novel antibody formulation
BR112013011699B1 (pt) * 2010-11-11 2019-04-24 Abbvie Biotechnology Ltd FORMULAÇÕES AQUOSAS LÍQUIDAS, SERINGA PRÉ-CHEIA OU DISPOSITIVO AUTOINJETOR E USO DAS DITAS FORMULAÇÕES PARA TRATAR UM DISTÚRBIO ASSOCIADO À ATIVIDADE DE TNFa COMPROMETIDA
EP2471554A1 (en) * 2010-12-28 2012-07-04 Hexal AG Pharmaceutical formulation comprising a biopharmaceutical drug
KR102061355B1 (ko) 2011-07-01 2019-12-31 바이오젠 엠에이 인코포레이티드 아르기닌-없는 tnfr : fc-융합 폴리펩티드 조성물 및 이용 방법
GB201112429D0 (en) * 2011-07-19 2011-08-31 Glaxo Group Ltd Antigen-binding proteins with increased FcRn binding
HK1200709A1 (en) 2012-03-07 2015-08-14 Cadila Healthcare Limited Pharmaceutical formulations of tnf-alpha antibodies
WO2013186230A1 (en) 2012-06-12 2013-12-19 Boehringer Ingelheim International Gmbh Pharmaceutical formulation for a therapeutic antibody
EP3701968A1 (en) * 2012-09-07 2020-09-02 Coherus Biosciences, Inc. Stable aqueous formulations of adalimumab
HK1214499A1 (zh) 2012-10-25 2016-07-29 Medimmune, Llc 穩定的低粘度抗體配製品
AR093297A1 (es) 2012-10-31 2015-05-27 Amgen Res Munich Gmbh Formulacion liquida que comprende un compuesto neutralizante de gm-csf
EP2727602A1 (en) 2012-10-31 2014-05-07 Takeda GmbH Method for preparation of a high concentration liquid formulation of an antibody
JP6339578B2 (ja) 2012-10-31 2018-06-06 タケダ・ゲー・エム・ベー・ハーＴａｋｅｄａ ＧｍｂＨ Ｇｍ−ｃｓｆ中和化合物を含む凍結乾燥製剤
SG10201802044RA (en) 2012-11-01 2018-05-30 Abbvie Inc Stable dual variable domain immunoglobulin protein formulations
CN104707146B (zh) 2013-12-16 2019-04-16 浙江海正药业股份有限公司 一种含有阿达木单抗的药物组合物
WO2015151115A1 (en) * 2014-04-02 2015-10-08 Intas Pharmaceuticals Limited Liquid pharmaceutical composition of adalimumab
ES2600488T3 (es) * 2014-05-23 2017-02-09 Ares Trading S.A. Composición farmacéutica líquida
ES2607489T3 (es) 2014-05-23 2017-03-31 Ares Trading S.A. Composición farmacéutica líquida
ES2572919T3 (es) 2014-05-23 2016-06-03 Ares Trading S.A. Composición farmacéutica líquida
CA3049857A1 (en) 2017-01-11 2018-07-19 Celltrion Inc. Stable liquid formulation

Also Published As

Publication number Publication date
EP2946765A1 (en) 2015-11-25
EP3476386B1 (en) 2024-01-24
MX2016015304A (es) 2017-02-22
CN106456538A (zh) 2017-02-22
CA3073703A1 (en) 2015-11-26
EP3476386A1 (en) 2019-05-01
EP2946765B1 (en) 2016-08-31
US10426832B2 (en) 2019-10-01
US20210196824A1 (en) 2021-07-01
SI3145487T1 (sl) 2018-10-30
SI2946765T1 (sl) 2016-11-30
RS57780B1 (sr) 2018-12-31
JP2017516846A (ja) 2017-06-22
HUE040237T2 (hu) 2019-02-28
US20170196974A1 (en) 2017-07-13
US20210121566A1 (en) 2021-04-29
SMT201800454T1 (it) 2018-11-09
IL263473B (en) 2021-05-31
PT2946765T (pt) 2016-11-10
ES2600488T3 (es) 2017-02-09
EP3145487A1 (en) 2017-03-29
US20200016268A1 (en) 2020-01-16
RU2016150640A (ru) 2018-06-26
RU2016150640A3 (pl) 2018-12-07
AU2018220051A1 (en) 2018-09-06
US20210322551A1 (en) 2021-10-21
EP3050557A1 (en) 2016-08-03
AU2020203119A1 (en) 2020-05-28
KR20210108504A (ko) 2021-09-02
HRP20181479T1 (hr) 2018-11-02
KR20170005864A (ko) 2017-01-16
US10729769B2 (en) 2020-08-04
US11707524B2 (en) 2023-07-25
JP6334819B2 (ja) 2018-05-30
RU2719431C2 (ru) 2020-04-17
US20210030871A1 (en) 2021-02-04
BR122021022508B1 (pt) 2023-04-11
LT3145487T (lt) 2018-09-25
IL249115A0 (en) 2017-01-31
SG10201806300VA (en) 2018-08-30
BR112016026879A8 (pt) 2021-06-29
CN109248315B (zh) 2021-11-09
BR112016026879A2 (pt) 2017-08-15
EP3476386C0 (en) 2024-01-24
HRP20161311T1 (hr) 2016-12-02
US11712471B2 (en) 2023-08-01
US20210308262A1 (en) 2021-10-07
LT2946765T (lt) 2016-11-25
CA2946953C (en) 2021-05-18
KR20230004960A (ko) 2023-01-06
CN109248315A (zh) 2019-01-22
SG10202000517YA (en) 2020-03-30
MX361061B (es) 2018-11-23
HUE029849T2 (en) 2017-04-28
RU2020112952A (ru) 2020-06-03
IL249115B (en) 2018-12-31
CY1120681T1 (el) 2019-12-11
IL263473A (en) 2019-01-31
SG11201608745QA (en) 2016-11-29
EP3145487B1 (en) 2018-08-22
RS55548B1 (sr) 2017-05-31
PT3145487T (pt) 2018-10-19
AU2015263340A1 (en) 2016-11-03
ES2971213T3 (es) 2024-06-04
AU2018220051B2 (en) 2020-06-04
KR102296766B1 (ko) 2021-09-03
KR20200017553A (ko) 2020-02-18
DK3145487T3 (en) 2018-10-01
AU2015263340B2 (en) 2018-08-09
DK2946765T3 (en) 2016-10-31
PL3145487T3 (pl) 2018-11-30
ES2687600T3 (es) 2018-10-26
CA2946953A1 (en) 2015-11-26
NZ725360A (en) 2019-09-27
IL282481A (en) 2021-06-30
WO2015177057A1 (en) 2015-11-26

Similar Documents

Publication Publication Date Title
IL282481A (en) A liquid pharmaceutical preparation
ZA201901590B (en) Liquid pharmaceutical composition
IL277241A (en) A liquid pharmaceutical preparation
ZA201901736B (en) Liquid pharmaceutical composition
GB201409471D0 (en) Pharmaceutical composition
IL249117A0 (en) A liquid pharmaceutical preparation
SG11201605366QA (en) Pharmaceutical composition containing pyridylaminoacetic acidcompound
GB201409488D0 (en) Pharmaceutical composition
EP3120835A4 (en) Liquid pharmaceutical composition
GB201409485D0 (en) Pharmaceutical composition
HUE048357T2 (hu) Pemetrexedet tartalmazó folyékony gyógyszerészeti kompozíció
LT3089740T (lt) Farmacinė kompozicija
SG10201504332VA (en) Pharmaceutical Composition
IL253572A0 (en) A liquid pharmaceutical preparation